Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Amgen | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Amgen

Revenues up 11% in the quarter and FY

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen
 
4Q Revenues: $4.4 billion (+11%)

4Q Earnings: $788 million (-16%)

YTD Revenues: $17.3 billion (+11%)

YTD Earnings: $4.3 billion (+18%)

Comments: Growth in the quarter was driven by sales of Enbrel (+23% to $1.2 billion), XGEVA (+7% to $215 million), and Prolia (+40% to $154 million). Combined Neulasta and Neupogen sales were down 1% in the quarter to $1.3 billion. Aranesp sales were down 9% to $489 million due to changes in practice patterns. EPOGEN sales were $479 million, down 1% due to a reduction in dose utilization. Sensipar/Mimpara sales increased 19% to $256 million in the quarter. Vectibix and Nplate sales increased 15% to $91 million and $101 million, respectively.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters